Posting of Report and Account

RNS Number : 7120Q

ReNeuron Group plc

09 August 2010

 



 

For Immediate Release

9 August 2010

ReNeuron Group plc

 

2009/10 Annual Report and Accounts

&

Notice of 2010 Annual General Meeting: 8 September 2010

Guildford, UK, 9 August 2010: ReNeuron Group plc (the "Company") (LSE: RENE.L) announces that its Annual Report and Accounts for the year ended 31 March 2010 and the Notice of the 2010 Annual General Meeting (AGM) have been sent to shareholders and are also available on the Company's website at www.reneuron.com. 

ReNeuron's AGM will be held at the offices of Morrison & Foerster (UK) LLP, 7th Floor, CityPoint, One Ropemaker Street, London, EC2Y 9AW on 8 September 2010 at 10.00 am.

Copies of the above documents have also been submitted to the UK Listing Authority for publication through the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

- Ends -

Enquiries:

Michael Hunt, Chief Executive Officer                                [phone]

ReNeuron Group plc

Lisa Baderoon, Mark Court, Isabel Podda

Buchanan Communications                                             [phone]

Emma Earl, Oliver Rigby

Daniel Stewart & Company plc                                         [phone]

Alastair Stratton, Tim Graham

Matrix Corporate Capital LLP                                           [phone]

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. A ground-breaking first-in-man clinical trial of ReN001 has recently commenced in the UK.  ReNeuron's ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

MSCUNOVRROAWRAR